...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Materials Research >G-protein-coupled receptors function as logic gates for nanoparticle binding using systems and synthetic biology approach
【24h】

G-protein-coupled receptors function as logic gates for nanoparticle binding using systems and synthetic biology approach

机译：使用系统和合成生物学方法，G蛋白偶联受体充当纳米颗粒结合的逻辑门

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

G-protein-coupled receptor 142 (GPR142) belongs to rhodopsin family. GPR142 and GPR119, both G(q)-coupled receptors, are expressed in pancreatic beta cells of pancreas; their activation eventually leads to triggering of insulin secretion. In this paper, through a systems and synthetic biology approach, the effect of a common hit compound has been investigated in GPR142 and GPR119 pathways. This hit that has the potential to be developed as a lead for nanodrug was obtained through high-throughput virtual screening. The hit compound was further docked with nanoparticles (GOLD, SPION, and CeO2). The probable effect of this potential hit on insulin secretion in type 2 diabetes and its dynamic behavior was explored. Kinetic simulation was performed for cross-validation of its role in both the pathways. This study opens up a probable avenue in therapy of type 2 diabetes through regulation of GPR142 and GPR119 receptors. The biological circuit constructed may further have an application as a modulator to control the up- and downregulation of the biochemical pathway and can be implemented as sensors or nanochips for therapy.
机译：G蛋白偶联受体142（GPR142）属于视紫红质家族。 GPR142和GPR119都是G（q）偶联受体，在胰腺胰腺β细胞中表达。它们的激活最终导致胰岛素分泌的触发。在本文中，通过系统和合成生物学方法，已在GPR142和GPR119途径中研究了常见命中化合物的作用。通过高通量虚拟筛选获得了这种有潜力被开发为纳米药物先导的命中。命中的化合物进一步与纳米颗粒（GOLD，SPION和CeO2）对接。探索了这种潜在的打击可能对2型糖尿病及其动态行为的影响。进行了动力学模拟，以交叉验证其在两种途径中的作用。这项研究通过调节GPR142和GPR119受体开辟了治疗2型糖尿病的可能途径。构造的生物回路可以进一步用作调节剂以控制生化途径的上调和下调，并且可以实现为用于治疗的传感器或纳米芯片。

著录项

  • 来源
    《Journal of Materials Research》 |2019年第11期|1854-1867|共14页
  • 作者

    Kaushik Aman Chandra; Mao Xueying; Li Cheng-Dong; Li Yan; Wei Dong-Qing; Sahi Shakti;

  • 作者单位

    Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China|Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China;

    Shanghai Univ, Qianweichang Coll, Shanghai 200444, Peoples R China;

    Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China|Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China;

    Henan Normal Univ, Coll Comp Sci & Informat Technol, Xixiang 453007, Peoples R China;

    Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai 200240, Peoples R China|Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China;

    Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201312, India;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    GPR119; GPR142; nanodrug; nanoparticle; synthetic biology; systems biology; type 2 diabetes;

    机译：GPR119;GPR142;纳米药物;纳米颗粒;合成生物学;系统生物学;2型糖尿病;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号